{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:33:06Z","timestamp":1769081586036,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":583,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiac resynchronization therapy (CRT) is an established treatment for drug-refractory heart failure (HF) in patients with left bundle branch block (LBBB). Acute haemodynamic improvement after CRT implantation may enable the intensification of HF medication soon thereafter. Immediate pharmacotherapy intensification (IPI) after CRT implantation achieves a synergetic effect, possibly leading to a better prognosis. This study aimed to explore the incidence, characteristics, and impact of IPI on real-world outcomes among CRT recipients with a history of hospitalization for acute HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This multicentre retrospective study enrolled CRT recipients with LBBB morphology, a QRS width \u2265120 ms, a left ventricular ejection fraction \u226435%, and New York Heart Association II\u2013IV HF symptoms. All patients had previous HF hospitalizations within the previous year and received guideline-directed medical therapy before CRT implantation. Patient baseline characteristics, including HF medication, were collected. IPI was defined as the intensification of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists within 30 days of CRT implantation. The primary endpoint was all-cause death or first hospitalization for HF; the secondary endpoint was all-cause death. We enrolled 194 patients (75% male; mean age, 65 \u00b1 13 years; 78% with non-ischaemic cardiomyopathy). One hundred five (54%) patients received IPI. Patients who received IPI exhibited a significantly shorter QRS duration (159 \u00b1 26 vs. 171 \u00b1 32 ms; P = 0.004), higher estimated glomerular filtration rate (55.2 \u00b1 20.0 vs. 47.8 \u00b1 24.7 mL\/min\/1.73 m2; P = 0.022), and more dilated cardiomyopathy. During a median follow-up period of 29 months, 70 (36%) patients reached the primary endpoint and 42 (22%) patients died. Patients with IPI showed significantly better outcomes for the primary and secondary endpoints than patients without IPI. The volumetric responder ratio at 6 months after implantation was not significantly different between patients with and without IPI; however, patients who received IPI had reduced mortality even at 6 months after implantation. In the multivariate analysis, IPI was an independent predictor of the primary endpoint (hazard ratio, 0.51; 95% confidence interval, 0.27\u20130.97; P = 0.043).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immediate intensification of HF medication was achieved in 54% of CRT recipients and was significantly higher in patients without excessive QRS prolongation, preserved renal function, and dilated cardiomyopathy than others. In patients with LBBB morphology and QRS \u2265 120 ms, IPI was associated with a significantly better prognosis and fewer HF hospitalizations after CRT implantation than others.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14737","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T21:43:15Z","timestamp":1710193395000},"page":"1888-1899","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immediate Pharmacotherapy Intensification After Cardiac Resynchronization Therapy: Incidence, Characteristics, and Impact"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3298-6586","authenticated-orcid":false,"given":"Kojiro","family":"Ogawa","sequence":"first","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Aonuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tsukuba Medical Center Hospital , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Metropolitan Bokutoh Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ibaraki Prefectural Central Hospital , Kasama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ibaraki Prefectural Central Hospital , Kasama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Nishina","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tsukuba Medical Center Hospital , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Metropolitan Bokutoh Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ieda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"2026012113134262400_ehf214737-bib-0001","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026012113134262400_ehf214737-bib-0002","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026012113134262400_ehf214737-bib-0003","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012113134262400_ehf214737-bib-0004","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/s0735-1097(03)01058-1","article-title":"Beta-blockers and angiotensin-converting enzyme inhibitors\/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada","volume":"42","author":"Johnson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012113134262400_ehf214737-bib-0005","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehi499","article-title":"Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: A report from the Euro Heart Survey on Heart Failure","volume":"26","author":"Lenzen","year":"2005","journal-title":"Eur Heart J"},{"key":"2026012113134262400_ehf214737-bib-0006","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2026012113134262400_ehf214737-bib-0007","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.amjcard.2011.03.060","article-title":"Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy","volume":"108","author":"Mullens","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012113134262400_ehf214737-bib-0008","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1253\/circj.CJ-20-0637","article-title":"JCS\/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias","volume":"2021","author":"Nogami","journal-title":"Circ J"},{"key":"2026012113134262400_ehf214737-bib-0009","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113134262400_ehf214737-bib-0010","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/s0735-1097(02)02337-9","article-title":"Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony","volume":"40","author":"Pitzalis","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026012113134262400_ehf214737-bib-0011","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2008.04.036","article-title":"Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response: A report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial","volume":"52","author":"Cleland","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012113134262400_ehf214737-bib-0012","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012113134262400_ehf214737-bib-0013","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1365-2362.2009.02217.x","article-title":"Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment","volume":"39","author":"Adlbrecht","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"2026012113134262400_ehf214737-bib-0014","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cardfail.2017.03.001","article-title":"Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy","volume":"23","author":"Martens","year":"2017","journal-title":"J Card Fail"},{"key":"2026012113134262400_ehf214737-bib-0015","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.hroo.2021.09.010","article-title":"Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement","volume":"O2","author":"Salimian","year":"2021","journal-title":"Heart Rhythm"},{"key":"2026012113134262400_ehf214737-bib-0016","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068124","article-title":"Differences in patient characteristics, clinical practice and outcomes of cardiac implantable electric device therapy between Japan and the USA: A cross-sectional study using data from nationally representative administrative databases","volume":"13","author":"Tonegawa-Kuji","year":"2023","journal-title":"BMJ Open"},{"key":"2026012113134262400_ehf214737-bib-0017","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.hrthm.2017.08.021","article-title":"Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology","volume":"15","author":"Martens","year":"2018","journal-title":"Heart Rhythm"},{"key":"2026012113134262400_ehf214737-bib-0018","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ejhf.563","article-title":"New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: Implications for cardiac resychronization therapy","volume":"19","author":"Braunschweig","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012113134262400_ehf214737-bib-0019","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacep.2017.02.021","article-title":"Sex-specific response to cardiac resynchronization therapy: Effect of left ventricular size and QRS duration in left bundle branch block","volume":"3","author":"Varma","year":"2017","journal-title":"J Am Coll Cardiol EP"},{"key":"2026012113134262400_ehf214737-bib-0020","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacc.2010.06.060","article-title":"Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy","volume":"57","author":"Van Bommel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012113134262400_ehf214737-bib-0021","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ahj.2010.02.023","article-title":"Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program","volume":"159","author":"O'Connor","year":"2010","journal-title":"Am Heart J"},{"key":"2026012113134262400_ehf214737-bib-0022","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: Problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012113134262400_ehf214737-bib-0023","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1161\/CIRCULATIONAHA.105.538272","article-title":"Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy","volume":"112","author":"Yu","year":"2005","journal-title":"Circulation"},{"key":"2026012113134262400_ehf214737-bib-0024","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/eurheartj\/eht514","article-title":"Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy","volume":"35","author":"Schmidt","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113134262400_ehf214737-bib-0025","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.003956","article-title":"Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: A meta-analysis","volume":"10","author":"Khan","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012113134262400_ehf214737-bib-0026","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212907","article-title":"Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis","volume":"14","author":"Turgeon","year":"2019","journal-title":"PLoS ONE"},{"key":"2026012113134262400_ehf214737-bib-0027","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.cir.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"2026012113134262400_ehf214737-bib-0028","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/s0195-668x(02)00743-1","article-title":"Bisoprolol dose\u2013response relationship in patients with congestive heart failure: A subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)","volume":"24","author":"Simon","year":"2003","journal-title":"Eur Heart J"},{"key":"2026012113134262400_ehf214737-bib-0029","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012113134262400_ehf214737-bib-0030","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1053\/hj.1998.v135.86971","article-title":"Vascular remodeling: The role of angiotensin-converting enzyme inhibitors","volume":"135","author":"Chrysant","year":"1998","journal-title":"Am Heart J"},{"key":"2026012113134262400_ehf214737-bib-0031","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/eurheartj\/ehv087","article-title":"The sympathetic\/parasympathetic imbalance in heart failure with reduced ejection fraction","volume":"36","author":"Floras","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012113134262400_ehf214737-bib-0032","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.hrthm.2023.03.1538","article-title":"2023 HRS\/APHRS\/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure","volume":"20","author":"Chung","year":"2023","journal-title":"Heart Rhythm"},{"key":"2026012113134262400_ehf214737-bib-0033","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1253\/circj.CJ-17-0234","article-title":"Survival and heart failure hospitalization in patients with cardiac resynchronization therapy with or without a defibrillator for primary prevention in Japan\u2014Analysis of the Japan Cardiac Device Treatment Registry Database","volume":"81","author":"Yokoshiki","year":"2017","journal-title":"Circ J"},{"key":"2026012113134262400_ehf214737-bib-0034","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012199","article-title":"Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: Outcomes in the ASIAN-HF registry","volume":"9","author":"MacDonald","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012113134262400_ehf214737-bib-0035","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026012113134262400_ehf214737-bib-0036","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113134262400_ehf214737-bib-0037","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113134262400_ehf214737-bib-0038","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113134262400_ehf214737-bib-0039","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jacep.2021.09.012","article-title":"CRT efficacy in \u201cmid-range\u201d QRS duration among Asians contrasted to non-Asians, and influence of height","volume":"8","author":"Varma","year":"2022","journal-title":"JACC Clin Electrophysiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/1888\/64526704\/eschf_11_4_1888.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/1888\/64526704\/eschf_11_4_1888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:15:24Z","timestamp":1769019324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/4\/1888\/8271164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,11]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14737","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"2023-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}